(SPANISH) ¿Cómo ha afectado el COVID-19 el diagnóstico de cáncer y qué puede hacer usted al respecto? Es hora de recordar la importancia de la detección temprana. En este video de discusión, el Dr. Narjust Duma habla con los Dres. Idalid “Ivy” Franco (Programa de Radiación Oncológica de Harvard), Ana Velázquez Manana (UCSF Helen Diller Family Comprehensive Cancer Center) y Luis Raez (Jefe de HematologÃa / OncologÃa y Director Médico – Memorial Cancer Institute) sobre cómo COVID 19 ha afectado la detección del cáncer en el comunidad latina, y la disminución en el diagnóstico de cáncer que se ha convertido…
Author: Editor
We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic of discussion is Checkmate 9LA – Opdivo (Nivolumab) and Yervoy (Ipilimumab) with Chemo vs. Chemo…
We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in small cell lung cancer. For this video, the topic of discussion is Checkmate 227 and the Opdivo Yervoy Combination trial update. For more, please visit…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic of discussion is new potential treatments for MET and RET positive non small cell lung cancer. For more,…
Alex F. Herrera, MD of the City of Hope speaks about the ASH 2020 abstract – 472 Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma.Introducing:Salvage therapy (tx) accompanied by autologous hematopoietic cell transplantation is the standard of treatment for patients (pts) with relapsed or refractory (RR) Hodgkin lymphoma (HL) (HCT). Most pts with high-risk RR HL can, however, relapse following HCT. The AETHERA study showed that post-HCT consolidation in high-risk HL pts with brentuximab vedotin (BV) improved progression-free survival (PFS) compared with placebo, particularly in pts with 2+ risk factors (Moskowitz,…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic of discussion is Enhertu and the potential for treatment of HER2 positive NSCLC. For more, please visit http://cancerGRACE.org/.…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic is Trial Updates – NSCLC and the SINDAS Trial – The Addition of SBRT to a Systemic EGFR…
For this addition to the GRACE Lung Cancer Video Library, Dr. Millie Das, Professor of Medicine, Division of Hematology and Oncology at UCSF in San Francisco joins us to discuss immunotherapy and if it has activity in malignant pleural mesothelioma. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic is Trial Updates – Anti-TIGIT and NSCLC PDL1, and the CITYSCAPE Trial – Adding Tiragolumab (Anti-TIGIT) to an…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon. Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic is the ADAURA Trial and it’s potential clinical impact; a potentially curative setting in adjuvant therapy for patients…
Elizabeth Budde, MD Ph.D. of the City of Hope discusses the ASH 2020 abstract – 1142 Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies.Introducing:In treating B-cell malignancies, bispecific antibodies that bridge lymphoma cells to T-cells have shown promise. However, toxicity, especially cytokine release syndrome (CRS), which can restrict dose intensity and efficacy, is associated with established T cell engaging antibodies. CRS results from T cell overstimulation, which can also result in subsequent downregulation of the function of T cells. IGM-2323 is a…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the current status of tumor mutational burden, or TMB. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Mukta Arora, MD, PI and Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota speaks about the ASH 2020 abstract – 358 Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment.Context:A significant cause of morbidity and late non-relapse mortality after allogeneic hematopoietic cell transplantation is chronic graft versus host disease (cGVHD) and is usually associated with prolonged immune suppression. There are few appropriate treatment options for patients (pts) with insufficient response to steroids and they reflect an unmet medical need. Severe toxicity, immunosuppression, and…
Andreas Hochhaus, MD of the Klinik für Innere Medizin II, Jena, Germany speaks about the ASH 2020 abstract – LBA-4 Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs). Introducing: Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor with a new mechanism of action, unlike all licensed TKIs binding to the ATP site of the BCR-ABL1 oncoprotein. In prospective clinical trials, BOS, an ATP-competitive TKI,…
Radhakrishnan Ramchandren, MD Investigator and Chief, Division of Hematology/Oncology from the University of Tennessee Medical Center discusses the ASH 2020 abstract – 2973 Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.IntroducingHistorically, almost all classical Hodgkin lymphoma (cHL) relapses occur during the first 5 years (Radford et al, BMJ 1997). In phase 3 ECHELON-1 trial (NCT01712490), treatment with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) significantly improved modified progression-free survival (PFS) compared to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients (pts) with newly diagnosed Stage III/IV cHL (Connors…
Amrita Krishnan, MD, FACP of the City of Hope speaks about the ASH 2020 abstract – 180 Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM).Context:MM eventually relapses and becomes refractory to therapy, indicating unmet needs in a patient (pt) population. Teclistamab (JNJ-64007957) is a BCMA x CD3 bispecific antibody which induces cytotoxicity mediated by T cells against BCMA-expressing MM cells. Results from the ongoing review of teclistamab in RRMM (NCT03145181) previously mentioned included a 67 percent objective response rate [ORR] for the intravenous 270 μg/kg dose…
Anthony S. Stein, MD of the City of Hope speaks about the ASH 2020 abstract – 192 Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML).Context:The method that provides the highest curative rate for acute myelogenous leukemia (AML) with moderate or high-risk cytogenetics is Allogeneic hematopoietic cell transplantation (alloHCT). Despite advances in prophylaxis and treatment, graft versus host disease (GvHD) has remained the key cause of post-transplantation mortality…
Fredrik Schjesvold, MD, Ph.D. from Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway speaks about the ASH 2020 abstract – 1411 Isatuximab Plus Pomalidomide and Dexamethasone in Frail Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis.Introducing:Multiple myeloma (MM) is a neoplastic disorder with a median age at diagnosis of 69 years that usually affects elderly patients (pts). Elderly pts are a heterogeneous group ranging from very delicate to exceptionally balanced with fitness. In many physiological processes, frailty is a condition of gradual deterioration, leading to reduced resistance to stressors,…
Constantine S. Tam, MD from Peter MacCallum Cancer Centre and St. Vincent’s Hospital and the University of Melbourne discusses the ASH 2020 Abstract – 2938 Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study.Context:Ibrutinib (ibr) is an inhibitor of Bruton’s tyrosine kinase (BTK) that is approved in the United States once daily for patients (pts) with mantle cell lymphoma (MCL) who have undergone approximately 1 previous therapy. Venetoclax (ven) is approved for pts with CLL or previously untreated AML as a BCL-2 inhibitor. In early-phase trials, Ibr+ven…
Rachel Grisham, MD of Memorial Sloan Kettering Cancer Center speaks about Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer.BOSTON—(BUSINESS WIRE)— Verastem Oncology, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company dedicated to advancing new medicines for cancer-fighting patients today announced the start of Phase 2 registry-directed clinical trial of its RAF/MEK inhibitor, VS-6766, and its FAK inhibitor, defactinib, in patients with recurrent low-grade serous ovarian cancer (LGSOC).The Phase 2 (GOG3052) study is a multicenter, parallel, randomized, open-label, adaptive, two-part multicenter trial assessing the efficacy and safety of VS-6766…
Brian Van Tine, MD, Ph.D. of Washington University of School of Medicine, in St. Louis speaks about Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma.Sarcoma type:Synovial sarcoma, Liposarcoma, (Myxoid/Round Cell Liposarcoma specifically)Places:London and ManchesterFull Title: A phase 2 open-label single-arm clinical trial of ADP-A2M4 SPEARTM T cells in subjects with advanced synovial sarcoma or liposarcoma of myxoid/round cellsAge: 16-75 to 75Step: Phase 2 Phase: Phase 2This research aims to find out if the drug ADP-A2M4 is safe and how well it works to target cancer cells from synovial sarcoma or Myxoid/Round Cell Liposarcoma.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Taofeek Owonikoko joins GRACE to discuss current updates in small cell lung cancer. In this video, Dr. Owonikoko discusses updated information on treatment options for relapsed sclc. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Stephen Liu joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Liu discusses updated information on the leading treatment options for patients with negative tumor pd l1. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this new addition to the GRACE Lung Cancer Video Library, Dr. Stephen Liu joins GRACE to discuss current updates in small cell lung cancer. In this video, Dr. Liu discusses updated information on immunotherapy for small cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Co-hosts Charu Aggarwal and Jack West are joined by Dr. Jamie Von Roenn and Christopher Merlan to discuss the landscape of virtual meetings, digital engagements and future of oncology meetings beyond the pandemic.
John Pagel, MD from the Swedish Cancer Institute & CLL Society Inc. discusses the ASH 2020 Abstract – 127 Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial.ContextMinimal residual disease (MRD) measurement is a proven and sensitive prognostic method for assessing the depth of response during and after chronic lymphocytic leukemia (CLL) treatment and for understanding the post-treatment dynamics of the disease. It is important to retrace these kinetics to understand which group of patients, despite the initial MRD response, is at risk of relapsing. To this end, an overview of the clonal growth trends…
John Mascarenhas, MD of the Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute speaks about the ASH 2020 Abstract – 55 CPI-0610, a Bromodomain, and Extraterminal Domain Protein (BET) Inhibitor, in Combination with Ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis Patients: Update of MANIFEST Phase 2 Study.The protein family of bromodomain and extraterminal domain (BET) binds to chromatin to guide the transcription of target genes involved in multiple pro-fibrotic pathways and is a novel therapeutic target for myelofibrosis fibrosis reduction (MF). CPI-0610 is a distinctive, first-in-class, oral small-molecule BET (BETi) protein inhibitor designed to promote disease-modifying activity through selective gene regulation…
John Mascarenhas, MD of the Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute speaks about the ASH 2020 Abstract – 53 Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor.Context:Myelofibrosis (MF) is a myeloproliferative neoplasm that is extreme and life-threatening. There are currently no accepted treatment options for patients who have relapsed or are refractory to (R/R) Janus kinase inhibitor (JAKi) therapy, and overall survival (OS) is dismal (range, 13-16 months). Imetelstat, a telomerase inhibitor, has shown clinical benefit in IMbark, a phase 2…
Peter Voorhees, MD – Director of Outreach for Hematologic Malignancies at Atrium Health’s Levine Cancer Institute speaks about ASH 2020 Abstract – 549 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy.Introducing:DARA, a human IgG Ange monoclonal antibody targeting CD38, is approved for relapsed/refractory multiple myeloma and NDMM as monotherapy and in conjunction with normal treatment regimens. In the primary review of the phase 2 GRIFFIN (NCT02874742) study, DARA plus RVd (D-RVd) significantly improved rigid complete response (sCR) rates in patients with…
Miles Prince, MD of Peter MacCallum Cancer Centre discusses the ASH 2020 abstract – The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.IntroducingThe phase 3 ECHELON-2 analysis (NCT01777152) showed that frontline therapy with brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) was superior in patients (pts) with systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL) to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (Horowitz S, et al. Lancet 2019). The hazard ratio (HR) (0.71…
Anthony Mato, MD of Memorial Sloan Kettering Cancer Center discusses ASH 2020 abstract – Oral presentation looking at real-world data from CLL patients on the informCLL registry (Abstract #547).Context:Treatment choices for pts with CLL have progressed and expanded with the advent of novel agents, along with guidance. The informCLLTM registry is the largest prospective observational registry of pts located in the US that received CLL/SLL treatment in the post-novel agent period. In order to analyze the effect of the complex care landscape, treatment practices, and findings in routine clinical settings, this prospective real-world registry is ideally placed. Baseline features, prognostic…
Hope Rugo, MD of the University of California San Francisco speaks about the SABCS abstract – FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10).KENILWORTH, N.J.—(BUSINESS WIRE)—Outside of the United States and Canada, Merck (NYSE: MRK), known as MSD, today reported that the U.S. KEYTRUDA, Merck’s anti-PD-1 therapy in conjunction with chemotherapy, has been approved by the Food and Drug Administration (FDA for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive…
Douglas Blayney, MD, Professor of Medicine (Oncology) of Stanford University Medical Center discusses the SABCS 2020 abstract – The Timing of Chemotherapy-Induced Neutropenia and Its Clinical and Economic Impact.A major toll on cancer patients is caused by chemotherapy-induced neutropenia (CIN) and its complications. Lengthy hospitalizations, early death, and high treatment costs are associated with febrile neutropenia (FN), a symptom of life-threatening infections. Furthermore, neutropenia is the primary cause of dose reduction and dose delay, reducing the delivery of chemotherapy in patients with potentially curable malignancies at maximum dose and on schedule, and thereby undermining long-term survival. Many recent studies in…
Chirag Shah, MD from the Cleveland Clinic discusses the SABCS 2020 abstract – DCIS biosignature reclassified patients who met RTOG 9804 or ECOG-ACRIN E5194 Ê»low-riskʼ clinicopathologic criteria into an elevated invasive risk group who benefited significantly from radiation therapy.ContextThe aim of treatment for DCIS is to prevent recurrences of local invasive breast cancer.Randomized DCIS clinical trials have shown that patients benefit from adjuvant radiation therapy (RT) following breast preservation surgery (BCS). However, the selection of treatment for DCIS patients remains a problem. Studies assessing successful risk and clinical-pathological characteristics have not found aGroup of patients with regard to local regulation,…
Yuan Yuan, M.D., Ph.D., Medical Oncologist at the City of Hope discusses the SABCS 2020 abstract – Phase I study of ipatasertib with chemotherapy and atezolizumab in patients with metastatic triple-negative breast cancer.BACKGROUNDOne of the most common cancer drivers of breast cancer is the pathway PI3K3-ATK.In patients(pts) with metastatic triple-negative breast cancers (mTNBCs), the AKT inhibitor ipatasertib (ipat) has shown great efficacy.The preclinical PDX model demonstrated synergy in TNBC2 between carboplatin and ipat.Synergies between atezolizumab and ipatasertib3 were demonstrated in previous clinical trials.The current Phase I trial is intended to assess the protection and effectiveness of the following combinations of…
Nicholas J. Short, MD Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center speaks about the ASH 2020 abstract 988 A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy.ContextPevonedistat is the first small-molecule, developmentally downregulated protein 8 (NEDD8)-activating enzyme-activating neural precursor cell inhibitor to be expressed (NAE). Inhibiting NAE inhibits the ubiquitination upstream of the proteasome of select proteins. Pevonedistat therapy disrupts the progression of the cell cycle and cell survival, leading to…
Neetu Gupta, Ph.D., MSc, BSc from the Cleveland Clinic speaks about the ASH 2020 abstract – 1447 Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS).Context:The FDA has approved CAR T-cells that target CD19 for the treatment of relapsed/refractory large B cell lymphoma (r/r LBCL). The advantage of this strategy is also complicated by potentially serious toxicities, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome, despite clinical effectiveness in chemo-refractory patients (ICANS). The physiological basis of…
Kimberly C Jenkins, MSNM from the Cleveland Clinic discusses the ASH 2020 abstract – 3441 Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic.Context:We developed a pilot program that monitors efficiency independently of the SARS-CoV-2 pandemic, enabling research coordinators (RCs) to work from home. However, all RCs were ordered to operate from home beginning on March 25, 2020, with the start of the pandemic. At the same time, all monitoring visits to in-person clinical trial sites were banned, forcing sponsors to either suspend study monitoring operations (10 percent) or adapt to remote monitoring (90 percent…
Anna Sureda, MD, Ph.D. of the Blood Cell Barcelona speaks about the ASH 2020 abstract – 2973 Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.IntroducingHistorically, almost all classical Hodgkin lymphoma (cHL) relapses occur during the first 5 years (Radford et al, BMJ 1997). In phase 3 ECHELON-1 trial (NCT01712490), treatment with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) significantly improved modified progression-free survival (PFS) compared to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients (pts) with newly diagnosed Stage III/IV cHL (Connors et al, NEJM 2018). In the…
Jason Valent, MD of the Cleveland Clinic speaks about the ASH 2020 abstract – 729 Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis.Context:CAEL-101 is an IgG1 monoclonal AL amyloid fibril reactive antibody with the potential for therapeutic immune clearance of AL amyloid deposits in patients with AL amyloidosis (AL). No major toxicity was found in the phase I analysis of CAEL-101 at doses of up to 500 mg/m2 IV administered weekly for 4 weeks as a…
Thierry Facon, MD from the Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille discusses the ASH 2020 abstract – 551 The Phase 3 TOURMALINE-MM2 Trial: Oral Ixazomib, Lenalidomide, and Dexamethasone (IRd) Vs Placebo-Rd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM).ContextIn transplant-ineligible NDMM patients, continuous Rd-based regimens are among the standards of care. These patients are diverse, ranging from fit 70-plus-year-olds to elderly and/or frail patients with poor performance status, requiring individual patient settings to be adapted to treatment. The continuous or higher cumulative dose use of proteasome inhibitors (PIs) leads to improved long-term…
Raymond Comenzo, MD – Director, Transfusion Services, Tufts Medical Center; Director, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center; Professor, Tufts University School of Medicine discusses the ASH 2020 abstract – Full results from the pivotal Phase 3 ANDROMEDA study, illustrating the promise of Darzalex Faspro as the first potential treatment for patients with ​pdf icon AL amyloidosis (Abstract #552).Context:The deposition of insoluble amyloid fibrils produced by light chains synthesized by clonal CD38+ plasma cells is characterized by systemic AL amyloidosis. In patients with AL amyloidosis, the combination of daratumumab (DARA) with bortezomib, cyclophosphamide, and dexamethasone (VCd) has…
Mehul Dalal, Ph.D. Takeda Oncology discusses ASH 2020 abstract – 2979 Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma.Context:Just half of the patients with relapsed/refractory (R/R) cHL are cured with salvage chemotherapy accompanied by stem cell transplantation, prompting clinical advancements in classical Hodgkin lymphoma (cHL) (SCT). Most studies to date have been performed in Europe or North America and there is minimal evidence from other regions on patient trends and clinical outcomes. The findings of the International Multi-center Retrospective Review of Treatment PractIces and OutComes (B-HOLISTIC) B-CD30+ HOdgkin Lymphoma, which examined…
Joshua Zeidner, MD from the University of North Carolina, Lineberger Comprehensive Cancer Center discusses the ASH 2020 abstract – 2191 Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes.IntroducingP-2001, a randomized phase 2 trial (NCT02610777), examined the efficacy and safety of pevonedistat (P), the first small molecule NEDD8-activating enzyme inhibitor, in combination with azacitidine (A) versus A alone in higher-risk patients (pts) with myelodyspla (Revised International Prognostic Scoring System risk >3, including intermediate [approximately 5% blasts], high or very high risk) The P-2001…
John N. Allan, MD – Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital discusses ASH 2020 abstract – Presentation of pooled analyses looking at the durability of responses in patients with high-risk CLL (Abstract #2219)Context:A strong negative predictor of survival in patients (pts) with CLL is the existence of TP53 aberration (defined as del(17p) or TP53 gene mutation). In pts with CLL carrying TP53 aberrations, first-line chemoimmunotherapy is suboptimal, with 3-year progression-free survival (PFS) and overall survival (OS) rates of just 18 percent and 38 percent, with fludarabine, cyclophosphamide,…
John Kuruvilla, MD of the Princess Margaret Cancer Centre and the University of Toronto speaks about ASH 2020 abstract – 374 Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study.Introducing:There is a lack of patient-reported results (PROs) in cHL, particularly those gathered prospectively in clinical trials. In addition, patients (pts) with cHL may experience B symptoms that can lead to decreased HRQoL, such as fever, night sweats, and weight loss. An open-label, international, randomized, phase 3 trial, KEYNOTE-204…
Michael Wang, MD from The University of Texas MD Anderson Cancer Center discusses the ASH 2020 abstract – Acalabrutinib Monotherapy in Patients with Relapsed/Refractory MCL: Long-Term Efficacy and Safety Results from a Phase 2 Study.Context:Acalabrutinib (acala) is a highly selective, covalent, next-generation inhibitor of Bruton tyrosine kinase (BTK) approved for patients (pts) with mantle cell lymphoma (MCL) who have undergone approximately 1 prior therapy. In a single-arm phase 2 analysis (ACE-LY-004; NCT02213926), the efficacy and protection of acala in relapsed/refractory (R/R) MCL pts was demonstrated following a median follow-up of 26 mo (Wang M, et al. Leukemia. 2019;33:2762-6). Here, after…
Christian Buske, MD – Medical Director Comprehensive Cancer Center and Institute of Experimental Cancer Research of the University Hospital of Ulm discusses ASH 2020 abstract – 336 Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom’s Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study.Context:Ibrutinib is an inhibitor of Bruton tyrosine kinase approved once daily in the US and EU, either as a single agent therapy or in conjunction with rituximab (R) for the treatment of patients (pts) with Waldenström macroglobulinemia (WM) across all treatment lines. In the iNNOVATE (PCYC-1127; NCT02165397) phase 3 trial, ibrutinib demonstrated…
William G. Wierda, MD, Ph.D. – Professor Department of Leukemia, University of Texas MD Anderson Cancer Center speaks about ASH 2020 abstract – The first presentation of disease-free survival results from the CAPTIVATE study evaluating Imbruvica plus venetoclax as a time-limited treatment in first-line CLL (Abstract #123).Context:In a randomized phase 3 trials in first-line CLL studies, Ibr is a proven standard of care in CLL and is the only once-daily Bruton tyrosine kinase inhibitor with a substantial overall survival benefit (RESONATE-2; ECOG1912). The synergistic combination of Ibr + Ven (oral BCL2 inhibitor) has been shown to mobilize and clear CLL…